+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Bioprocess Optimisation & Digital Biomanufacturing market is expected to reach $68.9bn by 2029” says new Visiongain report

28 February 2020
Pharma

Visiongain has launched a new pharma report Global Bioprocess Optimisation & Digital Biomanufacturing Market Forecast.

The Global market for bioprocess optimisation and digital biomanufacturing is favoured by the increasing global population which by 2050 will be predominately 65 years and above. There is also a growing demand for biologics drugs and biosimilar drugs which has compelled manufacturers to introduce technologies that would help bring the drugs to the market at a far more rapid pace than before.

The lead analyst of the report commented "The Bioprocess Optimization and Digital Manufacturing market is expected to witness a robust growth during the years of forecast owing to rise in biosimilars, growing complexity of drug manufacturing and patent expiry of blockbuster drugs coupled with rising cost containment pressure on biopharmaceutical players which is also expected to improve the uptake of digitally advanced products for manufacturing. With respect to the technology market, the analytical and process control technologies are expected to witness the highest growth during the forecast period. The bioreactors market is expected to foresee the highest growth during the forecast period."

Leading companies featured in the report include ABB, 3M Co., Danaher Corporation, Agilent Technologies, Applikon Technology, Sartorius Stedium Biotech, Shimadzu Corp., Siemens Healthcare and many others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Stem Cell Technologies and Applications Market Report 2022-2032

The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.

01 December 2022

Read

Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2023-2033

The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.

01 December 2022

Read

Visiongain Publishes Medical Imaging Market Report 2022-2032

The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.

30 November 2022

Read

Visiongain Publishes Antibody Drug Conjugates Market Report 2022-2032

The global antibody drug conjugates market was valued at US$3,668 million in 2021 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

28 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever